SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending amidst strong community anticipation for pivotal Phase 3 REGAL trial results for its GPS immunotherapy in AML, especially after the CEO's recent comments hinting at "curative outcomes." This fuels widespread speculation of an imminent Big Pharma buyout and a significant short squeeze, contrasting sharply with minority skepticism regarding the trial's blinded status and valuation.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is gaining attention as escalating geopolitical tensions, particularly regarding Iran and broader U.S.-China dynamics, intensify the focus on securing domestic heavy rare earth supplies for defense and high-tech industries. The community is actively anticipating the company's upcoming Bankable Feasibility Study, expected to re-rate its Greenland-based Tanbreez project's strategic value amidst calls for Western supply chain independence.

Americas Gold & Silver Corp. engages in the acquisition, exploration, development, and exploration of mineral resource properties. It operates through the following segments: Cosalá Operations, Galena Complex, Relief Canyon, and Corporate and Other. The Cosalá Operations segment operates in Mexico. The Galena Complex and Relief Canyon segments focuses on the United States. The company was founded by Peter Jude Hawley on May 12, 1998 and is headquartered in Toronto, Canada.

Americas Gold and Silver Corp

Americas Silver Corp

Americas Silver (USAS) is trending as silver prices surge amid strong industrial demand and geopolitical tensions, with a significant community focus on perceived market manipulation. The company's strategic joint venture for North America's first commercial antimony processing facility and increasing silver production are key talking points for investors anticipating future upside.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath (PATH) is trending with high anticipation for its upcoming earnings report, as its recent AIUC-1 certification highlights its role in secure enterprise AI agent orchestration, driving polarized community discussion and short-squeeze speculation.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is surging as intense short-covering and robust institutional accumulation are fueled by renewed optimism for its FDA-approved TIL therapy, Amtagvi, and imminent data readouts for pipeline expansion in lucrative oncology indications. The community widely anticipates a significant re-rating, potential international approvals, and strategic buyout interest, highlighting its perceived undervaluation.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending as it secures multiple significant contracts in nuclear energy, including SMR deployments and European research sites, alongside its crucial role in NASA's Artemis II mission, driving bullish long-term growth expectations backed by its substantial backlog. However, some investors express frustration over the stock's price action, labeling it "trash" and questioning its immediate upward momentum despite positive developments.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as a strong financial report confirms its shift to profitability through robust MIPLYFFA sales, fueling investor optimism for European approval and a potential M&A event, with the community actively debating the company's significant undervaluation.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines is generating significant buzz due to a recent $2.1 million defense order and its strategic investment in the Trump-backed XTEND merger, reinforcing its pivotal role in the expanding domestic drone industry. The community is keenly anticipating government contracts from the Drone Dominance Program, highlighting UMAC's low float, NDAA-compliant components, and potential for a substantial short squeeze.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending after reporting strong Q4 results that included robust e-commerce and advertising growth, a dividend increase, and a large share buyback, but also issued cautious forward guidance. This has led to a split community, with many bullish on its defensive nature and digital transformation, while others question its high valuation given the tempered outlook and its revenue milestone recently surpassed by Amazon.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors aggressively hedge against potential market weakness, fueled by escalating geopolitical tensions, rising oil prices, and widespread concerns about the sustainability of the "AI bubble" in the tech-heavy Nasdaq. Many in the community are actively positioning this 3x inverse ETF to capitalize on an anticipated broad market downturn and a potential "bloodbath."

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

RHHBY reports that giredestrant plus palbociclib misses the main PFS goal in a phase III first-line breast cancer study, though the combo shows a numerical improvement.

Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal

RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.

Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead?

CORT's Korlym 2025 sales rises 13% Y/Y, with 2026 revenues seen at $900M-$1B. However, the court ruling favoring Teva's generic may put pressure on future sales.

Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?

MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?

Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study

RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS.

Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates

SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.

The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT

Costco, Roche and Lam Research lead Zacks??? top stock reports, with standout gains and resilient fundamentals across sectors.

Top Stock Reports for Costco, Roche & Lam Research

Costco's resilient membership model, strong cash flow and e-commerce momentum position it to weather market turmoil and keep earnings growing.

FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug

FDA's acceptance of RHHBY's NDA for giredestrant plus everolimus in ER-positive breast cancer sets up a potential first oral SERD combo.

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics, and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '25	$1.62	--	--	N/A
Q4 '24	$1.11	--	--	N/A
Q1 '24	$1.41	--	--	N/A

RHHBY
Roche Holdings AG ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '25

Historical Earnings

Latest RHHBY News

RHHBYRoche Holdings AG ADR